The human’s natural immune system (called complement) has been found to be associated with the severity of COVID disease in people with age-related macular degeneration (AMD), according to a new study published in Nature Medicine. A hyperactive complement system is known to be directly related to development of AMD. In a retrospective observational study of […]
Beovu (brolucizumab) for wet AMD is the newest anti-VEGF drug on the market. It has been shown to be an effective and long-lasting inhibitor of blood vessel development (neovascularization) in the retina. The drug’s manufacturer has, however, been recently investigating incidences of severe intraocular inflammation (vasculitis) and retinal artery occlusion that were reported after their product […]
We reported here in October 2019 that Genentech had reported good Phase 2 trial results examining the use of their unique alternative to intravitreal injections. The Port Delivery System (PDS) is a tiny refillable implant that provides patients affected by wet (neovascular) age-related macular degeneration with continuous delivery of Lucentis as necessary. The company has […]
Since 2004, anti-VEGF drug injections have been shown to be highly effective in suppressing choroidal neovascularization (CNV) in the retinas of people with wet age-related macular degeneration and diabetic retinopathy. They have also been shown to suppress further CNV for as long as 12 weeks, depending upon the drug being used and the disease state […]
A survey of 2,000 adults in the U.S. has shown that 42% have used telehealth services in place of their regular in-person visits to eye clinics since the beginning of the COVID-19 pandemic in March 2020. Telehealth is a service made available by way of telecommunication devices like computers and smart phones. Using this recent […]
Lineage Cell Therapeutics (originally BioTime, Inc.) has announced positive results with its experimental OpRegen® therapy for geographic atrophy (GA), the advanced stage of dry macular degeneration. The company began enrolling and treating U.S.-based patients in 2017 under David S. Boyer, M.D. (Retina-Vitreous Associates Medical Group, Los Angeles) and H. Richard McDonald, M.D., (West Coast Retina […]
A procedure reported here in March 2018 has been shown to continue being a safe and effective method for introducing stem cells into the retina. Eye researcher Professor Pete Coffey, who founded the London Project over a decade ago, has confirmed that two study patients have maintained improvements in their vision five years after surgery. […]
People with severe vision loss can less accurately judge the distance of nearby sounds, potentially putting them more at risk of injury, according to new research published in the journal Scientific Reports. Researchers from Anglia Ruskin University’s Vision and Eye Research Institute (VERI) tested participants with different levels of vision loss, presenting them with speech, music […]
Genentech has announced positive top line results from its Phase III Archway study, evaluating Port Delivery System (PDS) with Lucentis (ranibizumab) in people living with wet (neovascular)AMD. PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customized formulation of Lucentis over a period of months. […]
A article in the journal Nature has reported that scientists from Hong Kong and the U.S. have taken a big step toward development of a true bionic eye, more precisely called a “biomimetic electrochemical eye”. Attempts that set it apart from other such efforts, such as the Argus 2 device, are its similarity to many of […]
Reprinted from Prevent Blindness For everyone’s health and safety, ophthalmologists, optometrists, and other doctors are being urged to see patients only for urgent or emergent problems during the coronavirus pandemic. This is important for two reasons: To limit contact between patients and staff in offices, waiting rooms, exams rooms, and surgical facilities to reduce the […]
Prevent Blindness is pleased to partner with Retina International to invite patients and caregivers to participate in online surveys which are being conducted in order to better understand patient perception and attitudes to the current care pathway for the treatment of neovascular (wet) age-related macular degeneration (wet AMD) as well as Diabetes-related Macular Edema (DME). […]
In March, we posted an article which suggested ways to keep busy in spite of low vision. As we continue through another month of mass quarantine, here are more suggestions contributed by an especially thoughtful reader in response to that article. Learn a language. Duolingo, a method used in the school system, can be downloaded […]
Photoreceptors are cells in the retina which convert light into nerve impulses. Because of them, we can see the world around us. The two types of photoreceptors are rod cells and cone cells. Rod cells are responsible for peripheral and night vision, and cone cells are responsible for central and color vision under bright conditions. […]
Support groups for people with blindness and low vision are important monthly events in hundreds of senior centers, clinics, retirement communities, and other venues for older adults. Recent public health concerns, however, are causing worries about attendance at these gatherings. MD Support has announced that its telephone support group, TeleSupport, is welcoming guest callers during […]
Pixium Vision reports that follow-up from 18 to 24 months after implantation showed that their PRIMA Bionic Vision System sustainably elicited light perception in all four dry AMD patients with favorable safety profile. Moreover, the second-generation transparent glasses, enabling to combine natural peripheral vision and prosthetic vision, greatly benefited patients and their visual acuity by 3 […]
Many doctors are restricting clinic visits to urgent or emergent problems during the coronavirus pandemic. Are anti-VEGF injections considered urgent? What qualifies as an emergency? Should I let my eye physician know if I am showing symptoms of COVID-19? I’m in a clinical trial. Should I continue to participate? Prevent Blindness provide answers to these […]
Nano Retina has announced preliminary results for first-in-human implantation of its NR600 artificial retina device. The first two patients to receive the device in March 2020 reported visual effect. The NR600 mimics the natural physiological processes of the human eye and restores functional vision to persons blinded by retinal degenerative diseases, including age-related macular degeneration […]
“Social distancing? Not a problem,” remarked an elderly member of my low vision support group. “I’ve been socially distant for years.” “Absolutely,” said another. “The toughest issue with being alone was originally what to do to fill my time, but I’ve gotten pretty good at that.” The session then took a detour from my planned […]
A Summary of a Quarter-Century of Low Vision Research and Development Presented to the International Low Vision Support Groupby Dan Roberts, Director Macular Degeneration Support, the charitable parent corporation of our International Low Vision Support Group, is celebrating its 25th year as a leading resource for people affected by macular degeneration and similar diseases leading […]
Information from the National Eye Institute A protein that normally deposits mineralized calcium in tooth enamel may also be responsible for calcium deposits in the back of the eye in people with dry age-related macular degeneration (AMD), according to a study from researchers at the National Eye Institute (NEI). This protein, amelotin, may turn out […]
Patients who are undergoing anti-VEGF treatment with Beovu (brolucizumab) for wet AMD should be aware that the drug is currently being investigated by the drug’s manufacturer, Novartis, for potential adverse events in some patients. Beovu was approved for clinical use in October 2019, and it has since shown to be an effective and long-lasting inhibitor […]
A study concluded in 2019 suggests that some patients with wet AMD can retain good visual acuity with no treatment for at least 3 years after stopping anti-VEGF treatment. Researchers compared two groups from the 2008-2009 Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). The first group was comprised of patients who had been released […]
RIBOMIC, Inc. has announced that the first patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States. Currently approved therapies […]
This is becoming a common question among people who have been treated for years with anti-VEGF drug therapy. These eye injections are the gold standard for treatment of wet age-related macular degeneration (wAMD), having been first used clinically in 2004. The news is good. A recent retrospective review in the U.K. has found that almost […]
Researchers have discovered a protein that might be related to the cause of age-related macular degeneration (AMD) and thus provide insight into early diagnosis and treatment. The study, published in Nature Communications, was a collaboration of Queen Mary University of London, the University of Manchester, Cardiff University, and Radboud University Medical Center, Nijmegen. High levels […]
For over two decades, eye health organizations have worked diligently to increase awareness of the high risks of macular degeneration from tobacco smoking. Now, the recently-released 2020 Surgeon General’s report has revealed that the work of those organizations is paying off. Americans are doing better at making good choices when it comes to smoking. According […]
Macugen. Lucentis. Avastin. Eylea. Beovu. All of those are anti-VEGF drugs prescribed for treatment of wet AMD and other conditions involving growth and leakage of new blood vessels in the retina. Those brand names appear in articles and ads, but rarely in eye specialists’ notes and prescription orders. Such names are designed mainly for public […]
A National Eye Institute (NEI) study will test the safety of a stem cell treatment for the dry (atrophic) form of age-related macular degeneration (AMD). The researchers will take a patient’s own blood cells, and in a lab, convert them into induced pluripotent stem cells (iPSC) capable of becoming any type of cell in the […]
Investigators have found significant associations between lessened brain functions and age-related macular degeneration (AMD). 5604 people age 40+ who participated in the 2005-2008 National Health and Nutrition Examination Survey have been found to experience increased memory problems and confusion, seemingly as a result of their AMD. The report was published in the December 2019 issue […]
As reported here in 2017, a drug called RGX-314 is being tested as a one-time sub-retinal injection for wet age-related macular degeneration (wAMD). A preliminary study showed that patients with wAMD had long-term vision stabilization and anatomic improvement following a single treatment with the investigational gene therapy. Now, in a subgroup of patients with the […]
Genentech has reported end-of-trial results examining the use of their unique alternative to intravitreal injections, the Port Delivery System (PDS). As reported previously here, the PDS is a tiny refillable implant that provides patients affected by wet age-related macular degeneration (AMD) with continuous delivery of Lucentis (ranibizumab) as necessary. Presented by Carl Regillo, MD, at […]
A Phase 2 study has found that a new drug could be a safe and effective treatment for improving vision in patients with dry age-related macular degeneration (AMD). On October 13, 2019, David Boyer, MD (Retina-Vitreous Associates Medical Group), presented results from a study of risuteganib intravitreal injection to members of the American Academy of […]
(Updated 10/12/19) Adverum Biotechnologies, Inc. has announced progress with yet another therapy designed to extend the time between anti-VEGF injections for treatment of wet age-related macular degeneration (wAMD). The company’s Investigational New Drug (IND) application has been approved for a multi-center study of ADVM-022, a novel gene therapy candidate for the treatment of wAMD. “We […]